SCHEMBL7910561

SCHEMBL7910561

C[C@H](NC(=O)C1(c2ccccc2)CCN(C(=O)c2ccc(N3CCS(=O)(=O)CC3)cc2)CC1)c1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
LMNA P02545 3/20 0.46
NPY1R P25929 1/20 0.43
SLC6A4 P31645 1/20 0.43
KCNH2 Q12809 1/20 0.43
GRIN2B Q13224 1/20 0.41
TSHR P16473 3/20 0.41
CCR1 P32246 1/20 0.41
HSP90AA1 P07900 1/20 0.40
NAMPT P43490 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALOX15 P16050 1/20 0.39
ATM Q13315 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7907440 0.94 TSHR (0.44) ALDH1A1NPY1RTSHRCA12CA1
SCHEMBL13092248 0.91 MEN1 (0.45) ALDH1A1NPY1RSLC6A4TSHRHSP90AA1
SCHEMBL7914218 0.87 HSP90AA1 (0.42) ALDH1A1LMNATSHRHSP90AA1NAMPT
SCHEMBL13092179 0.85 PIN1 (0.47) ALDH1A1TSHRCA12CA1CA2
SCHEMBL13092193 0.84 TSHR (0.47) ALDH1A1NPY1RTSHRCA12CA1
SCHEMBL7901820 0.84 TSHR (0.46) ALDH1A1NPY1RTSHRCA12CA1
SCHEMBL7908783 0.83 TSHR (0.55) ALDH1A1TSHRCA12CA1CA2
SCHEMBL13092252 0.82 TSHR (0.42) ALDH1A1TSHRCA12CA1CA2
SCHEMBL7900592 0.82 NPY1R (0.45) ALDH1A1NPY1RSLC6A4KCNH2GRIN2B
SCHEMBL13092555 0.82 CCR1 (0.48) ALDH1A1LMNANPY1RSLC6A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 ALDH1A1 480/4885LMNA 4690/4885NPY1R 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.